Neurelis Drug Patent Portfolio
Neurelis owns 1 orange book drug protected by 12 US patents Given below is the list of Neurelis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12599611 | Methods And Compositions For Treating Seizure Disorders In Pediatric Patients | 10 Jun, 2042 | Active |
| US12324852 | Administration of benzodiazepine compositions | 16 Oct, 2032 | Active |
| US12337061 | Administration of benzodiazepine compositions | 13 Jun, 2032 | Active |
| US11241414 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US11793786 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US12268664 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US12521400 | Administration Of Benzodiazepine Compositions | 27 Mar, 2029 | Active |
| US8895546 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US9763876 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US8927497 | Absorption enhancers for intranasal administration | 21 Jul, 2025 | Expired |
| US10265402 | Absorption enhancers for drug administration | 11 May, 2025 | Expired |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent | 11 May, 2025 | Expired |
Latest Legal Activities on Neurelis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Neurelis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 20 Jan, 2026 | US12521400 |
| Recordation of Patent eGrant | 13 Jan, 2026 | US12521400 |
| Mail Patent eGrant Notification | 13 Jan, 2026 | US12521400 |
| Patent Issue Date Used in PTA Calculation | 13 Jan, 2026 | US12521400 |
| Email Notification | 13 Jan, 2026 | US12521400 |
| Patent eGrant Notification | 13 Jan, 2026 | US12521400 |
| Email Notification | 01 Jan, 2026 | US12521400 |
| Issue Notification Mailed | 30 Dec, 2025 | US12521400 |
| Application Is Considered Ready for Issue | 11 Dec, 2025 | US12521400 |
| Dispatch to FDC | 11 Dec, 2025 | US12521400 |
| Email Notification | 10 Dec, 2025 | US12521400 |
| Mail Response to 312 Amendment (PTO-271) | 10 Dec, 2025 | US12521400 |
| Issue Fee Payment Verified | 05 Dec, 2025 | US12521400 |
| Issue Fee Payment Received | 05 Dec, 2025 | US12521400 |
| Email Notification | 26 Nov, 2025 | US12521400 |
Neurelis's Drug Patent Litigations
Neurelis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 29, 2019, against patent number US9763876. The petitioner Aquestive Therapeutics, Inc. formerly Monosol RX, LLC, challenged the validity of this patent, with Neurelis, Inc. as the respondent. Click below to track the latest information on how companies are challenging Neurelis's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11241414 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US11793786 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US8895546 | January, 2025 |
Trial Instituted
(16 Sep, 2025)
| Neurelis, Inc. | Padagis US LLC et al. |
| US9763876 | January, 2019 |
Final Written Decision
(06 Aug, 2020)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Institution Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Institution Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
Neurelis's Family Patents
Neurelis Drug List
Given below is the complete list of Neurelis's drugs and the patents protecting them.
1. Valtoco
Valtoco is protected by 12 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12599611 | Methods And Compositions For Treating Seizure Disorders In Pediatric Patients |
10 Jun, 2042
(15 years from now)
| Active |
| US12324852 | Administration of benzodiazepine compositions |
16 Oct, 2032
(6 years from now)
| Active |
| US12337061 | Administration of benzodiazepine compositions |
13 Jun, 2032
(5 years from now)
| Active |
| US11241414 | Administration of benzodiazepine compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US11793786 | Administration of benzodiazepine compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US12268664 | Administration of benzodiazepine compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US12521400 | Administration Of Benzodiazepine Compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US8895546 | Administration of benzodiazepine compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US9763876 | Administration of benzodiazepine compositions |
27 Mar, 2029
(2 years from now)
| Active |
| US8927497 | Absorption enhancers for intranasal administration |
21 Jul, 2025
(a year ago)
| Expired |
| US10265402 | Absorption enhancers for drug administration |
11 May, 2025
(1 year, 2 months ago)
| Expired |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
11 May, 2025
(1 year, 2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valtoco's drug page